Expanded Prostate Cancer Index Composite for Clinical Practice: Development and Validation of a Practical Health Related Quality of Life Instrument for Use in the Routine Clinical Care of Patients With Prostate Cancer (original) (raw)
Quality of Life Research, 2014
Purpose The objective was to obtain a standardized evaluation of available prostate cancer-specific quality of life instruments used in patients with early-stage disease. Methods We carried out systematic literature reviews in the PubMed database to identify manuscripts which contained information regarding either the development process or metric properties of prostate cancer-specific quality of life instruments. Each instrument was evaluated by two experts, independently, using the Evaluating Measures of Patient-Reported Outcomes (EMPRO) tool. An overall and seven attribute-specific EMPRO scores were calculated (range 0-100, worst to best): measurement model, reliability, validity, responsiveness, interpretability, burden and alternative forms. Results Eight instruments and 57 manuscripts (2-15 per instrument) were identified. The Expanded Prostate Cancer Index Composite (EPIC) was the best rated (overall EM-PRO score 83.1 points). Good results were also obtained by University of California Los Angeles-Prostate Cancer Index (UCLA-PCI), Patient-Oriented Prostate Utility Scale (PORPUS) and Prostate Cancer Quality of Life Instrument (PC-QoL) with 77.3, 70.5 and 64.8 points, respectively. These four instruments passed with distinction the validity and responsiveness evaluation. Insufficient reliability results were observed for UCLA-PCI and PORPUS. Conclusions Current evidence supports the choice of EPIC, PORPUS or PC-QoL. Attribute-specific EMPRO results facilitate selecting the adequate instrument for every purpose. For longitudinal studies or clinical trials, where responsiveness is the priority, EPIC or PC-QoL should be considered. We recommend the PORPUS for economic evaluations because it allows cost-utility analysis, and EPIC short versions to minimize administration burden.
Health Related Quality of Life in Men With Prostate Cancer
The Journal of Urology, 2003
Purpose: Quality of life is of great concern to patients considering treatment options for prostate cancer. In the absence of clinical trial data clearly demonstrating that a particular treatment is superior to another for localized prostate cancer, in terms of cause specific survival, patients may value quality of life as much as quantity of life. The goal of this review is to familiarize the reader with the methodology of quality of life research and to review the recent literature on quality of life outcomes in prostate cancer.
Health and Quality of Life Outcomes, 2019
Background: This study aims to validate and evaluate the psychometric properties and reliability of the Italian version of the Expanded Prostate Cancer Index Composite-Short Form (EPIC-26), a measure of quality of life (QoL) for prostate cancer patients. Methods: Two hundred and eighty-four prostate cancer patients completed the Italian version of the EPIC-26 questionnaire at 45 days (T1) and 3 months (T2) after robot-assisted radical prostatectomy (RARP). Psychometric properties were evaluated using structural equation modeling: the goodness of fit of the correlated five-factor model (CFFM) for the EPIC-26 was assessed using the confirmatory factor analysis (CFA), while longitudinal invariance was conducted to assess the ability of the EPIC-26 to measure QoL construct over time. Test-retest reliability was assessed as well by considering intraclass correlations. Results: At T1, the CFFM model displayed a good fit to data. Similarly, the model showed an adequate fit also at T2. Results of the reliability analysis attested the acceptable internal consistency and test-retest reliability of each dimension: all Cronbach's alphas could be classified as acceptable (i.e., above .65) except for low Cronbach's alpha for hormonal dysfunction at T1 (i.e., .638) and urinary irritation at both waves. (i.e., respectively .585 and .518). Finally, psychometric properties were invariant over time and each of the five dimensions of QoL displayed from moderate (all ICCs above .500) to good test-retest reliability (i.e. ICC for urinary incontinence = .764). Conclusions: Results of the CFA and the measurement invariance analysis demonstrated the validity of the Italian version of the EPIC-26 to assess QoL in prostate cancer patients. Its reliability and good psychometric qualities are well-supported, thus providing a valid tool to assess health-related quality of life and its change over time in prostate cancer patients.
A New Measurement Scale for Evaluating Health-Related Quality of Life in Men with Prostate Cancer
Iraqi National Journal of Nursing Specialties
Objectives: This study aimed to identify and study most properties of the specific and general health-relatedquality-of-life (HRQoL) in prostate cancer patients, as well as creating a new measurement scale for assessing QoLamong prostate cancer patients.Methodology: A cross sectional (descriptive) study was conducted to evaluate General Quality of life in patientswith prostate cancer. A sample of 100 prostate cancer patients from Al-Amal National hospital for cancermanagement and Oncology Center in Baghdad Medical City. This study applied format of General World HealthOrganization Quality of Life-BERF questionnaire. The methods used descriptive statistics to evaluate the GeneralQoL-Improvements, as well as inferential statistical methods were used such that (Wilcoxon Signed Rank,McNemar).Results: Patients with prostate cancer have different assessment concerning general QoL, and have instability oftheir daily life cycle, within a moderate level. Regarding Specific QoL, overall resul...
Principle Component Analysis of Health-Related Quality of Life Measures for Prostate Cancer
Juntendo Medical Journal, 2016
The aim of this study is to elucidate underlying distinctive common features of currently used measures. Patients: This study was conducted as a part of nationwide cross-sectional and observational study of"Prostate cancer background, quality of life (QOL), patientʼs satisfaction and treatment survey by Japan Prostate Cancer Study Group (J-CaP)". PCa survivors were invited to answer Short Form 36 (SF-36), Expanded Prostate Cancer Index Composite (EPIC), Functional Assessment of Cancer Therapy (FACT) through the web page of J-CaP. Methods: Significant conceptual components of three health-related quality of life (HRQoL) questionnaires: EPIC, FACT, and SF-36 were identified by principle component analysis in Japanese patients. Results: All of the questions from EPIC, FACT, and SF-36 were classified into 9 categories by principle component analysis. Our result suggests that a more feasible and integrated HRQoL measure can be created based on those components identified in our study. Conclusion: Three HRQoL questionnaires containing 128 questions in total could be narrowed down to 9 principle components. Our future assignment is to create an integrated and more feasible version of scoring system that comprehensively covers these 9 components.